Vaccines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 576 - 576
Published: March 2, 2023
Background:
Since
the
advent
of
global
COVID-19
vaccination,
several
studies
reported
cases
encephalitis
with
its
various
subtypes
following
vaccinations.
In
this
regard,
we
conducted
a
systematic
review
to
investigate
and
characterize
clinical
settings
these
aid
in
physician
awareness
proper
care
provision.
Methods:
We
systematically
searched
PubMed,
Web
Science,
Scopus
manually
Google
Scholar.
Studies
published
until
October
2022
were
included.
Demographic
data,
features,
vaccine
treatment
lines,
outcomes
extracted.
Results:
A
total
65
patients
from
52
The
mean
age
was
46.82
±
19.25
years,
36
(55.4%)
males.
AstraZeneca
most-reported
associated
(38.5%)
followed
by
Pfizer
(33.8%),
Moderna
(16.9%),
others.
Moat
occurred
after
first
dose
vaccination
41/65
(66.1%).
time
between
symptom
onset
9.97
7.16
days.
Corticosteroids
(86.2
%)
immunosuppressants
(81.5
most
used
lines
treatment.
majority
affected
individuals
experienced
full
recovery.
Conclusion:
Our
study
summarizes
current
evidence
post-vaccination
encephalitis,
regarding
presentation,
symptoms
onset,
management,
outcomes,
comorbid
conditions;
however,
it
fails
either
acknowledge
incidence
occurrence
or
establish
causal
relationship
vaccines
encephalitis.
JMIR Public Health and Surveillance,
Journal Year:
2024,
Volume and Issue:
10, P. e49695 - e49695
Published: Feb. 27, 2024
Community
engagement
plays
a
vital
role
in
global
immunization
strategies,
offering
the
potential
to
overcome
vaccination
hesitancy
and
enhance
confidence.
Although
there
is
significant
backing
for
community
health
promotion,
evidence
supporting
its
effectiveness
promotion
fragmented
of
uncertain
quality.
Human Vaccines & Immunotherapeutics,
Journal Year:
2024,
Volume and Issue:
20(1)
Published: March 6, 2024
Various
novel
platform
technologies
have
been
used
for
the
development
of
COVID-19
vaccines.
In
this
nested
cohort
study
among
healthcare
workers
in
Australia
and
Brazil
who
received
three
different
COVID-19-specific
vaccines,
we
(a)
evaluated
incidence
adverse
events
following
immunization
(AEFI);
(b)
compared
AEFI
by
vaccine
type,
dose
country;
(c)
identified
factors
influencing
AEFI;
(d)
assessed
association
between
reactogenicity
anti-spike
IgG
antibody
responses.
Of
1302
participants
homologous
2-dose
regimens
ChAdOx1-S
(Oxford-AstraZeneca),
BNT162b2
(Pfizer-BioNTech)
or
CoronaVac
(Sinovac),
1219
(94%)
completed
reaction
questionnaires.
Following
first
dose,
any
systemic
was
higher
recipients
(374/806,
46%)
with
(55/151,
36%;
p
=
0.02)
(26/262,
10%;
<
0.001)
recipients.
After
second
(66/151,
44%)
(164/806,
20%;
(23/262,
9%;
risk
younger
participants,
females,
Australia,
varied
type
dose.
Prior
did
not
impact
AEFI.
Participants
reported
a
local
(170/231,
74%
vs
222/726,
31%,
(171/231,
328/726,
45%,
0.001),
regardless
type.
primary
course
vaccination,
report
seroconverted
at
similar
rate
to
those
reactions.
conclusion,
found
that
influenced
participant
age
differed
Brazil.
Journal of Medical Virology,
Journal Year:
2024,
Volume and Issue:
96(7)
Published: July 1, 2024
Globally,
the
rollout
of
COVID-19
vaccine
had
been
faced
with
a
significant
barrier
in
form
hesitancy.
This
study
adopts
multi-stage
perspective
to
explore
prevalence
and
determinants
hesitancy,
focusing
on
their
dynamic
evolutionary
features.
Guided
by
integrated
framework
3Cs
model
(complacency,
confidence,
convenience)
EAH
(environmental,
agent,
host),
this
conducted
three
repeated
national
cross-sectional
surveys.
These
surveys
carried
out
from
July
2021
February
2023
across
mainland
China,
targeted
individuals
aged
18
older.
They
were
strategically
timed
coincide
critical
vaccination
phases:
universal
coverage
(stage
1),
partial
2),
key
population
3).
From
2023,
examined
sample
sizes
29
925,
6659,
5407,
respectively.
The
hesitation
rates
increased
8.39%
29.72%
2023.
Urban
residency,
chronic
condition,
low
trust
developer
contributed
hesitancy
pandemic.
Negative
correlations
between
intensity
policies
positive
long
COVID,
confirmed.
provides
insights
for
designing
future
effective
programs
emerging
vaccine-preventable
infectious
X
diseases.
Vaccines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 575 - 575
Published: March 2, 2023
Dengue
represents
a
major
public
health
concern.
With
effective
vaccines
in
development,
it
is
important
to
identify
motivational
factors
maximize
dengue
vaccine
uptake.
A
cross-sectional,
quantitative,
electronic
survey
was
administered
nationally
representative
adult
population
(n
=
3800)
Argentina,
Brazil,
Colombia,
Mexico,
Indonesia,
Malaysia,
and
Singapore.
Willingness
vaccinate
against
dengue,
Knowledge,
Attitudes,
Practices
(KAP)
toward
vector
control,
prevention,
vaccination
were
determined.
The
Capability,
Opportunity,
Motivation
for
Behavior
change
(COM-B)
framework
used
correlated
with
vaccine(s)
KAP
scores
(standardized,
0-100%
scale)
resulted
low
global
score
Knowledge
(48%)
Practice
(44%),
moderate
Attitude
(66%);
comparable
across
countries.
Of
all
respondents,
53%
had
high
willingness
(Score:
8-10/10)
which
higher
(59%)
Latin
America
(Argentina,
Mexico)
than
Asia
Pacific
(40%)
(Indonesia,
Singapore).
Key
significantly
(p
<
0.05)
associated
increased
included
accessibility
the
(subsidies
incentives)
trust
healthcare
system
government.
common
approach
prevention
endemic
countries--with
some
country-specific
customization,
including
education,
vaccination,
control
(multi-pronged)--may
reduce
burden
improve
outcomes.
Vaccines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 576 - 576
Published: March 2, 2023
Background:
Since
the
advent
of
global
COVID-19
vaccination,
several
studies
reported
cases
encephalitis
with
its
various
subtypes
following
vaccinations.
In
this
regard,
we
conducted
a
systematic
review
to
investigate
and
characterize
clinical
settings
these
aid
in
physician
awareness
proper
care
provision.
Methods:
We
systematically
searched
PubMed,
Web
Science,
Scopus
manually
Google
Scholar.
Studies
published
until
October
2022
were
included.
Demographic
data,
features,
vaccine
treatment
lines,
outcomes
extracted.
Results:
A
total
65
patients
from
52
The
mean
age
was
46.82
±
19.25
years,
36
(55.4%)
males.
AstraZeneca
most-reported
associated
(38.5%)
followed
by
Pfizer
(33.8%),
Moderna
(16.9%),
others.
Moat
occurred
after
first
dose
vaccination
41/65
(66.1%).
time
between
symptom
onset
9.97
7.16
days.
Corticosteroids
(86.2
%)
immunosuppressants
(81.5
most
used
lines
treatment.
majority
affected
individuals
experienced
full
recovery.
Conclusion:
Our
study
summarizes
current
evidence
post-vaccination
encephalitis,
regarding
presentation,
symptoms
onset,
management,
outcomes,
comorbid
conditions;
however,
it
fails
either
acknowledge
incidence
occurrence
or
establish
causal
relationship
vaccines
encephalitis.
